Open in interactive viewer → charts, metric popovers & call review

Terumo's Record Core, Ruptured Aortic

A voluntary recall and a third guidance cut obscure a record adjusted-profit half — and raise the question of how many more operational surprises are buried in the portfolio.
4543.T · Earnings Call · 2026-11-12

The headline is not the business — until it is

Terumo's second-quarter FY2026 report landed with two truths that do not fit neatly together. The core franchise is growing: first-half revenue reached a record ¥624.5bn, up 17%, and adjusted operating profit hit a record ¥147.3bn, up 29%. Reported operating profit, however, fell 30% to ¥70.8bn because of ¥76.4bn of impairment and related charges tied to the terminated CSL Plasma supply agreement. Management then cut full-year operating profit guidance by ¥41bn to ¥119bn, after an October cut linked to CSL and an August increase linked to tariff refunds and litigation settlement proceeds. The company now expects ¥87.5bn of profit for the year. The market is being asked to look through a pile of one-time items; the question is whether the pile is actually one-time.

A recall that is company-unique, not a sector wave

The fresh shock is Terumo Aortic. In September, pre-shipment testing found endotoxin levels above specification in stent grafts made at the Bolton plant. Terumo suspended shipments of RelayPlus, RelayPro and TREO in all markets and began a voluntary recall. The scope is broad because the recall covers all products manufactured at the same site, not a single Relay model. Management estimates a roughly ¥8bn revenue hit and ¥41bn operating-profit hit, including ¥38bn of asset-valuation risk tied to Bolton's fixed assets, intangibles and R&D assets. The root cause has not been found.

The cause is still under investigation. It is difficult to fully determine the scope of the potential impact.

Hikaru Samejima, CEO · 2026-11-12
Analysts pressed on FDA inspection risk and whether the product could effectively disappear for a year; the CFO conceded that for the next fiscal year, “this year's product level shipment could be difficult.” — Jin Hagimoto, CFO · 2026-11-12 This is not a market-wide theme. The global keyword set is crowded with tariff, AI-data-center and rate language; voluntary recall does not appear as a broad wave. It is a Terumo-specific operating failure.

The pattern behind the one-offs

What makes the recall more than a single bad quarter is the pattern. In February, asked about CSL and Rika, management said it did “not see significant changes in our projections” — Unknown Executive, Executive (likely senior management) · 2026-02-13. By October, Terumo had terminated the CSL Plasma supply agreement and booked the ¥76.4bn charge. In the same prior call, management said Rika was “proceeding on plan steadily” — Unknown Executive, Executive (likely senior management) · 2026-02-13; by the current call, plasma innovation was being scaled down in the second half. The new impairment losses and the supply agreement termination are therefore not isolated accounting events. They are the third leg of a recurring story: Terumo keeps discovering that a manufacturing or partner relationship is less stable than the prior call implied. The current call's own language reinforces the caution. The CFO says the ¥41bn Aortic charge includes risks that are “not yet confirmed as of today” — Jin Hagimoto, CFO · 2026-11-12 and were included “as a very cautious measure” — Jin Hagimoto, CFO · 2026-11-12. That is prudent, but it also means the guidance cut is partly a reserve against a future the company cannot yet quantify. The adjusted operating profit forecast — ¥271.5bn, still 24% growth — is the number management wants investors to anchor on. The gap between adjusted and reported profit is now the story.

The growth offsets are real, but they carry their own operational risk

Terumo is not standing still. It completed the Arsenal Medical acquisition for about $250m plus contingent consideration, adding NeoCast, a liquid embolic for middle meningeal artery embolization in chronic subdural hematoma. That extends Terumo Neuro from cerebral aneurysm and acute ischemic stroke into an adjacent market. In Blood and Cell Technologies, management showcased Spectra Optia and Reveos, with TBCT revenue growing at a 14% CAGR from FY21 to FY25, or 5% in local currency excluding plasma innovations, and a roughly $1.2bn serviceable addressable market for Reveos in FY26. These are credible growth platforms. But the same segment is where the next bottleneck sits. Terumo Neuro's Costa Rica plant is short of trained staff because competitors have opened large factories nearby. The CFO described “a very active work labor market” — Jin Hagimoto, CFO · 2026-11-12 and said training new workers takes three to four months. This is a temporary supply constraint, not a demand problem, but it echoes the Costa Rica quality/regulatory issues that analysts have asked about for years. On a prior call, management said a follow-on inspection produced “no additional request from the authorities” — Unidentified Company Representative, Company Representative · 2025-08-07. The plant has now become a supply bottleneck for a different reason. That is the kind of operational whack-a-mole that makes a record adjusted margin less comforting than it looks.

What to watch

The next catalyst is the GS31 strategy update on December 15, where management will lay out the next five-year growth plan. It arrives with the Aortic investigation unresolved, the CSL termination still working through the P&L, and the Leverkusen CDMO plant still in its ramp-up phase. The bull case is that Terumo's core — TIS, Global Blood Solutions, Organ Technologies and Hospital Care Solutions — is growing fast enough to absorb these hits, and that the recall is a contained, if expensive, quality event. The bear case is that the company has now had multiple guidance revisions in a single fiscal year, each driven by a different operational surprise, and that the adjusted-profit narrative is doing too much work. For a $23.6bn market-cap medtech, that is a lot of explaining.